Patients with nonalcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) suffer from higher surgical morbidity and posthepatectomy liver failure, according to a new Singapore study.
The immunotherapeutic human papillomavirus (HPV) vaccine tipapkinogen sovacivec (TS) provided complete histologic resolution of cervical intraepithelial neoplasia (CIN) grade 2/3, offering a potential nonsurgical option for cervical precancerous lesions which could stretch to other HPV-associated precursors or cancers in the future, a new study shows.
The histone deacetylase inhibitor tucidinostat, when used in combination with exemestane for treating patients with advanced, HR-positive, HER2-negative breast cancer, prolongs progression-free survival and substantially increases overall response and clinical benefit, while having a manageable safety profile, as shown in the results of the phase III ACE trial.
Kuala Lumpur will play host to the 6th Asia-Pacific Congress of Interventional Oncology 2019 (APCIO 2019) on 2–5 October. Interventional Oncology (IO) is a minimally invasive subspecialty offering various advanced and state-of-art services in the management of oncological disorders. IO is recognized as the fourth pillar in oncology and it has undergone tremendous technological growth in the last two decades. Numerous minimally invasive procedures are available in this subspecialty, offering another dimension of advanced cancer care.
Asian countries face the largest burden of childhood cancer in terms of disability-adjusted life-years (DALYs), according to a recent analysis of the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) 2017.
Clinical trials of chimeric antigen receptor (CAR) T-cell therapy in haematological malignancies are to commence in Hong Kong following completion of the city’s first CAR T-cell laboratory to be built by the Chinese University of Hong Kong (CUHK).
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 20190807035449
Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.
Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1cof 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.
The US Food and Drug Administration (FDA) has given the greenlight to pembrolizumab as a monotherapy for recurrent locally advanced or metastatic squamous cell carcinoma of the oesophagus whose tumours express PD-L1.